Marx, W and Hockey, M and McGuinness, AJ and Lane, M and Christodoulou, J and van der Mei, I and Berk, M and Dean, OM and Taylor, B and Broadley, S and Lechner-Scott, J and Jacka, FN and Lucas, RM and Ponsonby, A-L and the RELIEF Trial team, The effect of emerging nutraceutical interventions for clinical and biological outcomes in multiple sclerosis: a systematic review, Multiple Sclerosis and Related Disorders, 37 Article 101486. ISSN 2211-0348 (2020) [Refereed Article]
Copyright 2019 Elsevier B.V.
Methods: In accordance with PRISMA reporting guidelines, a systematic literature search was conducted using three electronic literature databases. Risk of bias was assessed using the Jadad scale.
Results: Thirty-seven randomized controlled trials, investigating fourteen nutraceuticals, were included in the review. Trials that investigated alpha lipoic acid (n = 4/6), ginkgo biloba (n = 3/5), vitamin A (n = 2/2), biotin (n = 1/2), carnitine (n = 1/2), green tea (n = 1/2), coenzyme Q10 (n = 1/1), probiotics (n = 1/1), curcumin (n = 1/1), Andrographis paniculata (n = 1/1), ginseng (n = 1/1), and lemon verbena (n = 1/1) were reported to improve biological (e.g. MRI brain volume change, antioxidant capacity) and/or clinical (e.g. fatigue, depression, Expanded Disability Status Scale) outcomes in multiple sclerosis compared to control. However, most trials were relatively small (average study sample size across included studies, n = 55) and there were few replicate studies per nutraceutical to validate the reported results. Furthermore, some nutraceuticals (e.g. green tea and inosine) should be used with caution due to reported adverse events. Risk of bias across most studies was low, with 31 studies receiving a score between 4 and 5 (out of 5) on the Jadad Scale.
Conclusion: The existing literature provides preliminary support for the use of a number of nutraceutical interventions in MS. However, sufficiently powered long-term trials are required to expand the currently limited literature and to investigate unexplored nutraceuticals that may target relevant pathways involved in MS such as the gut microbiome and mitochondrial dysfunction.
|Item Type:||Refereed Article|
|Keywords:||dietary supplement, multiple sclerosis, nutraceutical, vitamin|
|Research Division:||Biomedical and Clinical Sciences|
|Research Field:||Central nervous system|
|Objective Group:||Clinical health|
|Objective Field:||Clinical health not elsewhere classified|
|UTAS Author:||van der Mei, I (Professor Ingrid van der Mei)|
|UTAS Author:||Taylor, B (Professor Bruce Taylor)|
|Web of Science® Times Cited:||4|
|Deposited By:||Menzies Institute for Medical Research|
Repository Staff Only: item control page